Warren Buffett's Successor, Greg Abel, Just Sold UnitedHealth Group Stock. Is He Missing a Huge Opportunity?

Berkshire Hathaway fully exited its roughly 5.1 million-share stake in UnitedHealth Group in Q1 2026, alongside sales of Amazon, Domino's Pizza, Mastercard, and Visa. The article argues the sale was reasonable despite UNH rising more than 40% since April 1, but notes the turnaround is still a work in progress and 2026 earnings growth expectations of about 12.3% may be hard to sustain. UnitedHealth trades near 21x forward earnings, and any shortfall in Medicare reimbursement gains or AI-driven cost savings could trigger another pullback.

Analysis

The key market signal is not the UNH sale itself, but the portfolio-preference shift it implies: capital is being rotated away from idiosyncratic operational turnarounds and into businesses with cleaner underwriting of earnings power. That is a subtle vote for names where management can control outcomes faster than regulators, reimbursement cycles, or claims inflation. In that sense, the incrementally bullish read is stronger for GOOGL and MA/V than for healthcare, because their secular growth drivers are less dependent on a single execution bridge.

UNH remains vulnerable to “good news exhaustion.” After a sharp rebound, the stock now needs repeated beats on medical cost ratio and Medicare economics just to hold the multiple; a 1-2 point miss on margin assumptions can compress the valuation multiple more than investors expect. The second-order risk is that any AI-led overhead savings may be offset by higher utilization or tougher reimbursement scrutiny, leaving earnings growth mathematically plausible but economically fragile over the next 2-4 quarters.

The more interesting contrarian angle is that Berkshire’s exit may be less a bearish statement on the franchise and more a recognition that the near-term catalyst path is asymmetric to the downside after the rally. If the market has already priced the turnaround, the stock can continue to grind higher only if 2026 guidance proves conservative and Medicare pricing stays favorable; otherwise, the path of least resistance is sideways-to-down. That makes this a name to own only if you have conviction that margin normalization is sustainable, not just transient.

For the rest of the basket, the relative signal is constructive for payment networks and GOOGL, where balance-sheet strength and product leverage support compounding. AMZN looks more exposed to being the funding source for portfolio simplification than a beneficiary, while DAL and M appear to be tactical reallocations rather than high-conviction structural buys.

Key Decisions for Investors

• Fade the post-rally move in UNH: initiate a 1-3 month put spread or short against strength if the stock retests recent highs, targeting a pullback toward the low- to mid-400s on any margin disappointment; risk/reward improves if implied vol remains elevated.
• Long MA / V versus UNH as a 3-6 month pair: payment networks have cleaner secular compounding and less regulatory earnings noise; use UNH as the short leg to express skepticism about fragile healthcare turnaround economics.
• Add to GOOGL on weakness over the next 2-8 weeks: the position change suggests capital is being reallocated toward businesses with operating leverage and AI optionality; risk is lower than UNH because earnings acceleration is not dependent on reimbursement policy.
• Avoid chasing UNH calls or momentum longs until the next earnings cycle clarifies medical cost trends; if you must own it, size as a trade, not a core position, with a predefined stop on any guidance miss.
• Treat DAL and M as tactical, not strategic: only engage on pullbacks, because these look like portfolio-recycling destinations rather than high-conviction long-duration allocators.